Last reviewed · How we verify
BP1.4979 active drug
BP1.4979 is a small molecule drug that targets the renin-angiotensin system.
BP1.4979 is a small molecule drug that targets the renin-angiotensin system. Used for Hypertension.
At a glance
| Generic name | BP1.4979 active drug |
|---|---|
| Also known as | BP1.4979 |
| Sponsor | Bioprojet |
| Drug class | ACE inhibitor |
| Target | ACE |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
BP1.4979 works by inhibiting the angiotensin-converting enzyme (ACE), which plays a key role in regulating blood pressure. This inhibition leads to a decrease in angiotensin II levels, resulting in vasodilation and a reduction in blood pressure. By targeting the renin-angiotensin system, BP1.4979 aims to provide a novel approach to managing hypertension.
Approved indications
- Hypertension
Common side effects
- Cough
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BP1.4979 active drug CI brief — competitive landscape report
- BP1.4979 active drug updates RSS · CI watch RSS
- Bioprojet portfolio CI